Obeticholic Acid may Improve outcomes in NASH-Related Liver Fibrosis

Written By :  Jacinthlyn Sylvia
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-01-07 15:45 GMT   |   Update On 2024-01-07 15:45 GMT
Advertisement

A new study published in Journal of Hepatology confirms the efficacy of Obeticholic Acid (OCA), a novel farnesoid X receptor agonist and antifibrotic agent against non-alcoholic steatohepatitis (NASH).

The Phase III REGENERATE trial originally reported results from an 18-month liver biopsy analysis involving OCA. The treatment demonstrated its efficacy, prompting further investigation. In this study, the potential of OCA was reaffirmed, providing hope for those battling this debilitating liver condition.

Advertisement

The study aimed to validate the previous findings and gather additional data to support OCA's effectiveness. A diverse panel of three pathologists independently evaluated digitized whole-slide images using the NASH Clinical Research Network scoring system. The primary endpoints were either an improvement of at least one stage in fibrosis without worsening of NASH or NASH resolution without worsening of fibrosis.

Among 931 participants, OCA demonstrated its potential with 22.4% achieving an improvement in fibrosis without NASH worsening, compared to only 9.6% on a placebo. Furthermore, 6.5% of those on OCA achieved NASH resolution without fibrosis progression, compared to 3.5% on the placebo.

Not only did OCA showcase its efficacy, but it also demonstrated a high degree of safety and tolerability. The study included data from 2,477 participants, and the incidence of treatment-emergent adverse events (TEAEs) and serious TEAEs was not substantially different across treatment groups. The most common TEAE reported was pruritus. Moreover, rates of hepatic, renal, and cardiovascular events were low and comparable across treatment groups.

These findings highlight OCA's potential to significantly impact the lives of patients with NASH-related liver fibrosis. Preventing fibrosis from progressing to cirrhosis or even reversing it is a critical goal in NASH treatment. OCA’s antifibrotic effects, proven effectiveness, and favorable safety profile offer hope for patients dealing with this challenging condition.

Source:

Sanyal, A. J., Ratziu, V., Loomba, R., Anstee, Q. M., Kowdley, K. V., Rinella, M. E., Knapple, W., Lawitz, E. J., Abdelmalek, M. F., Shiff, S. J., Sawhney, S., Capozza, T., … Younossi, Z. M. (2023). Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis. Journal of Hepatology, 79(5), 1110–1120. https://doi.org/10.1016/j.jhep.2023.07.014

Tags:    
Article Source : Journal of Hepatology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News